PharmiNews

The Directory of Pharma Companies and News

Alexion

Category:
Category:

Alexion News

DateNews
2017-01-09Alexion Submits U.S. and EU Applications Seeking Approval of Soliris® (Eculizumab) as a Treatment for Patients with Refr...
2017-01-06FDA Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (P...
2017-01-05Alexion to Present at the 35th Annual J.P. Morgan Healthcare Conference
2017-01-04Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016
2016-12-21Alexion Announces Top-Line Results from Phase 2/3 PROTECT Study of Eculizumab (Soliris®) for the Prevention of Delayed G...
2016-12-12Alexion’s Board of Directors Announces New Leadership Appointments
2016-12-04New Data from ALXN1210 Dose-Escalation Study Presented at ASH Show Rapid and Sustained Reductions in LDH in Patients wit...
2016-11-29Alexion to Present at the Citi 2016 Global Healthcare Conference
2016-11-17New Data from Global aHUS Registry Presented at ASN 2016 Show a Three-Fold Reduction in Post-Transplant Dialysis in Pati...
2016-11-16Alexion Receives NASDAQ Notification Related to the Late Filing of Form 10-Q
2016-09-23Alexion Employees Volunteer Together in Company’s First Global Day of Service
2016-09-13Alexion Launches Uncommon Strength Campaign to Unite and Celebrate the Courage and Resilience of People Living with Rare...
2016-08-29European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Dise...
2016-07-28Alexion Reports Second Quarter 2016 Results
2016-07-14Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive Assessments in Patients wit...
2016-07-11Alexion Pharmaceuticals to Report Second Quarter 2016 Results on Thursday, July 28, 2016
2016-07-07New Data from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (g...
2016-06-10Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Stu...
2016-06-06Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory General...
2016-06-01European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal H...
2016-05-19Researchers to Present Late-Breaking Data on ALXN1210 in Patients with PNH at EHA Annual Congress
2016-05-04Alexion to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
2016-04-28Alexion Reports First Quarter 2016 Results
2016-04-12Alexion Pharmaceuticals to Report First Quarter 2016 Results on Thursday, April 28, 2016
2016-04-04Data Presented at ENDO 2016 Show Sustained Improvements in Survival Rates, Bone Healing, Respiratory Support and Physica...
2016-03-28Kanuma® (sebelipase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Lysosomal Acid Lipase Defi...
2016-03-03New Data Presented at WORLDSymposium™ 2016 Show Substantial Survival Benefit Beyond 2 Years of Age in Infants with Lysos...
2016-03-01SBC-103 (rhNAGLU enzyme) Shows a 26.2 Percent Mean Reduction in Heparan Sulfate in Cerebrospinal Fluid at the Highest Do...
2016-02-29Alexion to Present at Upcoming Investor Conferences
2016-02-29Alexion Employees Across the Globe Join Together to Support Rare Disease Day 2016
2016-02-04Alexion to Present at the Leerink Partners 5th Annual Global Healthcare Conference
2016-02-03Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016
2016-01-20Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2015 Results on Wednesday, February 3, 2016
2016-01-15Researchers to Present New Data at ENDO 2016 Advancing the Understanding of Strensiq® (asfotase alfa) in Infants, Childr...
2016-01-04Alexion to Present at the 34th Annual J.P. Morgan Healthcare Conference
2015-12-10Alexion to Highlight Innovative Rare Disease Portfolio at Investor Day Meeting
2015-12-10Alexion Highlights Innovative Rare Disease Portfolio at Investor Day Meeting
2015-12-08FDA Approves Kanuma™ (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D)
2015-12-07Data from the International Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry Presented at ASH Annual Meeting Underscor...
2015-11-19Alexion to Highlight Robust Rare Disease Pipeline at Investor Day
2015-11-07Long-Term Follow-up Study Presented at ASN 2015 Supports Effectiveness of Soliris® (eculizumab) in Preventing Thrombotic...
2015-11-05Researchers to Present Data on Enhancing the Understanding of PNH and aHUS and Underscoring the Effectiveness of Soliris...
2015-10-29Alexion Reports Third Quarter 2015 Results
2015-10-23FDA Approves Strensiq™ (asfotase alfa) for Treatment of Patients with Perinatal-, Infantile- and Juvenile-Onset Hypophos...
2015-10-12Alexion Pharmaceuticals to Report Third Quarter 2015 Results on Thursday, October 29, 2015
2015-10-12Significant Improvements in Skeletal Mineralization and Physical Function Observed in Children with Hypophosphatasia (HP...
2015-10-02Alexion Announces Presentations at ASN 2015, Including a Long-Term Follow-Up Study of Soliris® (eculizumab) for the Prev...
2015-09-16Alexion Announces Presentations at 2015 American Society for Bone and Mineral Research Annual Meeting, Including New Dat...
2015-09-09New England Journal of Medicine (NEJM) Publishes Pivotal Phase 3 Data on Kanuma™ (sebelipase alfa) in Children and Adult...
2015-09-04Alexion Receives Notification of PDUFA Date Extension for Kanuma™ (sebelipase alfa)
2015-09-03Alexion to Present at the 2015 Morgan Stanley Global Healthcare Conference
2015-09-01European Commission Grants Marketing Authorization for Strensiq™ (asfotase alfa) for the Treatment of Patients with Pedi...
2015-09-01European Commission Grants Marketing Authorization for Kanuma™ (sebelipase alfa) for the Treatment of Patients of All Ag...
2015-07-30Alexion Reports Second Quarter 2015 Results
2015-07-13Alexion Pharmaceuticals to Report Second Quarter 2015 Results on Thursday, July 30, 2015
2015-07-06Strensiq® (asfotase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Hypophosphatasia (HPP)
2015-06-26Alexion Receives CHMP Positive Opinions for Strensiq™ (asfotase alfa) and Kanuma™ (sebelipase alfa) in the European Unio...
2015-06-23Alexion Completes Acquisition of Synageva
2015-06-22Alexion Accepts Shares of Synageva BioPharma Corp. Tendered Into Exchange Offer
2015-05-29Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexion’s Pending Acquisition of...
2015-05-06Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies f...
2015-05-05Researchers Present New Data from Phase 2 Clinical Trial of Eculizumab (Soliris®) in Prevention of Acute Antibody-Mediat...
2015-04-23Alexion Reports First Quarter 2015 Results
2015-04-13Alexion Announces Presentations at 2015 American Transplant Congress, Including Results from Studies Advancing the Under...
2015-04-09Alexion Pharmaceuticals to Report First Quarter 2015 Results on Thursday, April 23, 2015
2015-03-07New Data from First Natural History Study in Juveniles with Hypophosphatasia (HPP) Showing Substantial Disease Burden, I...
2015-03-02FDA Grants Priority Review for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia
2015-02-27Alexion Joins Patient Organizations Worldwide in Support of International Rare Disease Day 2015
2015-02-23Alexion to Present at Investor Conferences
2015-02-09New Data from a Natural History Study in Patients with Infantile- and Juvenile-Onset Hypophosphatasia Accepted as Late-B...
2015-02-05Alexion to Present at the 2015 Leerink Global Healthcare Conference
2015-01-29Alexion Appoints David L. Hallal as Chief Executive Officer, Effective April 1, 2015
2015-01-29Alexion Reports Fourth Quarter and Full Year 2014 Results and Provides Financial Guidance for 2015
2015-01-21Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2014 Results on Thursday, January 29, 2015
2015-01-20Researchers to Present New Data on Asfotase Alfa in Children with Hypophosphatasia (HPP) as well as Burden of Disease Da...
2015-01-07Alexion Provides Update on Phase 2 Clinical Trial with Eculizumab in Antibody Mediated Rejection (AMR) in Living-Donor K...
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.